Cargando…

Indications of Persistent Glycocalyx Damage in Convalescent COVID-19 Patients: A Prospective Multicenter Study and Hypothesis

The COVID-19 pandemic is caused by the SARS CoV-2 virus and can lead to severe lung damage and hyperinflammation. In the context of COVID-19 infection, inflammation-induced degradation of the glycocalyx layer in endothelial cells has been demonstrated. Syndecan-1 (SDC-1) is an established parameter...

Descripción completa

Detalles Bibliográficos
Autores principales: Vollenberg, Richard, Tepasse, Phil-Robin, Ochs, Kevin, Floer, Martin, Strauss, Markus, Rennebaum, Florian, Kabar, Iyad, Rovas, Alexandros, Nowacki, Tobias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619155/
https://www.ncbi.nlm.nih.gov/pubmed/34835130
http://dx.doi.org/10.3390/v13112324
_version_ 1784604921733054464
author Vollenberg, Richard
Tepasse, Phil-Robin
Ochs, Kevin
Floer, Martin
Strauss, Markus
Rennebaum, Florian
Kabar, Iyad
Rovas, Alexandros
Nowacki, Tobias
author_facet Vollenberg, Richard
Tepasse, Phil-Robin
Ochs, Kevin
Floer, Martin
Strauss, Markus
Rennebaum, Florian
Kabar, Iyad
Rovas, Alexandros
Nowacki, Tobias
author_sort Vollenberg, Richard
collection PubMed
description The COVID-19 pandemic is caused by the SARS CoV-2 virus and can lead to severe lung damage and hyperinflammation. In the context of COVID-19 infection, inflammation-induced degradation of the glycocalyx layer in endothelial cells has been demonstrated. Syndecan-1 (SDC-1) is an established parameter for measuring glycocalyx injury. This prospective, multicenter, observational, cross-sectional study analyzed SDC-1 levels in 24 convalescent patients that had been infected with SARS-CoV-2 with mild disease course without need of hospitalization. We included 13 age-matched healthy individuals and 10 age-matched hospitalized COVID-19 patients with acute mild disease course as controls. In convalescent COVID-19 patients, significantly elevated SDC-1 levels were detected after a median of 88 days after symptom onset compared to healthy controls, whereas no difference was found when compared to SDC-1 levels of hospitalized patients undergoing acute disease. This study is the first to demonstrate signs of endothelial damage in non-pre-diseased, convalescent COVID-19 patients after mild disease progression without hospitalization. The data are consistent with studies showing evidence of persistent endothelial damage after severe or critical disease progression. Further work to investigate endothelial damage in convalescent COVID-19 patients should follow.
format Online
Article
Text
id pubmed-8619155
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86191552021-11-27 Indications of Persistent Glycocalyx Damage in Convalescent COVID-19 Patients: A Prospective Multicenter Study and Hypothesis Vollenberg, Richard Tepasse, Phil-Robin Ochs, Kevin Floer, Martin Strauss, Markus Rennebaum, Florian Kabar, Iyad Rovas, Alexandros Nowacki, Tobias Viruses Article The COVID-19 pandemic is caused by the SARS CoV-2 virus and can lead to severe lung damage and hyperinflammation. In the context of COVID-19 infection, inflammation-induced degradation of the glycocalyx layer in endothelial cells has been demonstrated. Syndecan-1 (SDC-1) is an established parameter for measuring glycocalyx injury. This prospective, multicenter, observational, cross-sectional study analyzed SDC-1 levels in 24 convalescent patients that had been infected with SARS-CoV-2 with mild disease course without need of hospitalization. We included 13 age-matched healthy individuals and 10 age-matched hospitalized COVID-19 patients with acute mild disease course as controls. In convalescent COVID-19 patients, significantly elevated SDC-1 levels were detected after a median of 88 days after symptom onset compared to healthy controls, whereas no difference was found when compared to SDC-1 levels of hospitalized patients undergoing acute disease. This study is the first to demonstrate signs of endothelial damage in non-pre-diseased, convalescent COVID-19 patients after mild disease progression without hospitalization. The data are consistent with studies showing evidence of persistent endothelial damage after severe or critical disease progression. Further work to investigate endothelial damage in convalescent COVID-19 patients should follow. MDPI 2021-11-21 /pmc/articles/PMC8619155/ /pubmed/34835130 http://dx.doi.org/10.3390/v13112324 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Vollenberg, Richard
Tepasse, Phil-Robin
Ochs, Kevin
Floer, Martin
Strauss, Markus
Rennebaum, Florian
Kabar, Iyad
Rovas, Alexandros
Nowacki, Tobias
Indications of Persistent Glycocalyx Damage in Convalescent COVID-19 Patients: A Prospective Multicenter Study and Hypothesis
title Indications of Persistent Glycocalyx Damage in Convalescent COVID-19 Patients: A Prospective Multicenter Study and Hypothesis
title_full Indications of Persistent Glycocalyx Damage in Convalescent COVID-19 Patients: A Prospective Multicenter Study and Hypothesis
title_fullStr Indications of Persistent Glycocalyx Damage in Convalescent COVID-19 Patients: A Prospective Multicenter Study and Hypothesis
title_full_unstemmed Indications of Persistent Glycocalyx Damage in Convalescent COVID-19 Patients: A Prospective Multicenter Study and Hypothesis
title_short Indications of Persistent Glycocalyx Damage in Convalescent COVID-19 Patients: A Prospective Multicenter Study and Hypothesis
title_sort indications of persistent glycocalyx damage in convalescent covid-19 patients: a prospective multicenter study and hypothesis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619155/
https://www.ncbi.nlm.nih.gov/pubmed/34835130
http://dx.doi.org/10.3390/v13112324
work_keys_str_mv AT vollenbergrichard indicationsofpersistentglycocalyxdamageinconvalescentcovid19patientsaprospectivemulticenterstudyandhypothesis
AT tepassephilrobin indicationsofpersistentglycocalyxdamageinconvalescentcovid19patientsaprospectivemulticenterstudyandhypothesis
AT ochskevin indicationsofpersistentglycocalyxdamageinconvalescentcovid19patientsaprospectivemulticenterstudyandhypothesis
AT floermartin indicationsofpersistentglycocalyxdamageinconvalescentcovid19patientsaprospectivemulticenterstudyandhypothesis
AT straussmarkus indicationsofpersistentglycocalyxdamageinconvalescentcovid19patientsaprospectivemulticenterstudyandhypothesis
AT rennebaumflorian indicationsofpersistentglycocalyxdamageinconvalescentcovid19patientsaprospectivemulticenterstudyandhypothesis
AT kabariyad indicationsofpersistentglycocalyxdamageinconvalescentcovid19patientsaprospectivemulticenterstudyandhypothesis
AT rovasalexandros indicationsofpersistentglycocalyxdamageinconvalescentcovid19patientsaprospectivemulticenterstudyandhypothesis
AT nowackitobias indicationsofpersistentglycocalyxdamageinconvalescentcovid19patientsaprospectivemulticenterstudyandhypothesis